Increased Opportunities for Sales to Federal, State, and Local Government Agencies; Expected to Reduce Contracting Time

WAKEFIELD, Mass.–Implant Sciences Corporation (AMEX: IMX – News), a high technology supplier of sophisticated systems and sensors for the homeland security market and related industries, today announced the General Services Administration (“GSA”) has awarded the Company a GSA Schedule Contract for Schedule 84: Total Solutions For Law Enforcement, Security, Fire, Rescue, and Emergency/Disaster Response. The GSA Schedule, contract number GS-07F-0490U, allows Implant Sciences to provide its Quantum Sniffer™ QS-H150 Portable Explosives Detector to a wide range of government agencies as an approved, preferred vendor, and expedites the process of obtaining government purchases for its QS-H150 explosives detection system. The GSA Schedule is for an initial period of five years and the Company intends to begin quoting GSA contract prices and terms immediately.

According to GSA, purchases by government agencies off Schedule 84 totaled $2.2 billion in FY2007 with about $110 million in purchases of products in categories in which Implant Sciences expects to participate in the near term. In September 2007, the White House issued Homeland Security Presidential Directive/HSPD-19, which called for “…the development of a national strategy and implementation plan on the prevention and detection of, protection against, and response to terrorist use of explosives in the United States.” Implant Sciences believes that, in today’s world, explosives detection has become increasingly important for the safety and security needs of many nations.

“In light of Presidential Directive/HSPD-19, the fact that terrorism events continue around the world, and government agencies at all levels are looking for new, effective security systems, we are very pleased to have been awarded a GSA Schedule Contract,” said Phillip C. Thomas, President and CEO of Implant Sciences. “Obtaining a GSA Schedule Contract is expected to provide us with significant product sales opportunities within federal, state and local government agencies and contribute to our overall presence in the government market. Obtaining this broad-based contract is a key milestone in our growth strategy and as our product line grows, we expect to add additional products to the contract. We look forward to this opportunity to provide a wide range of U.S. government agencies with the same cost-effective solutions we believe are valued by our existing international and domestic customers.”

The QS-H150 provides high performance and reliability combined with a very low comparative cost of ownership. Annual maintenance costs are minimal and consist primarily of normal care and cleaning using common, low cost supplies. Calibration is autonomous, continuous, and requires no consumables. Since there are no radioactive materials used in the QS-H150, there are no associated certifications, licenses, inspections, or end-of-life disposal issues for users to contend with. As such, customers have an outstanding, cost effective product available to them in support of efforts to improve their overall security profile and meet mission critical objectives.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for the Security, Safety and Defense (SS&D) industries. The Company has developed proprietary technologies used in its commercial portable and bench-top explosive trace detection systems which ship to a growing number of locations domestically and internationally. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

Safe Harbor Statement

This press release contains certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause the Company’s actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the Company’s ability to successfully sell its QS-H150 products to government agencies authorized to procure goods and services from the GSA schedule, the inability of the Company to expand and strengthen its governmental distribution channel, the risk that the Company will not realize the anticipated benefits of the GSA schedule, and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K.

For further information, you are encouraged to review Implant Sciences’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2007 and Quarterly Reports for the periods ended September 30, 2007, December 31, 2007 and March 31, 2008. The Company assumes no obligation to update the information contained in this press release.